The CD3 complex consists of five subunits (γ, δ, ε, ζ, η) with molecular weights ranging from 16–28 kDa. The ε chain (CD3E), encoded by the CD3E gene on chromosome 11q23, is a 207-amino-acid transmembrane protein essential for TCR assembly and signal transduction . Recombinant monoclonal antibodies like clone SK7 (Biotium) and 6G6K9 (Thermo Fisher) bind specifically to the extracellular domain of CD3ε, enabling precise targeting without cross-reactivity to other CD3 subunits .
CD3E antibodies modulate T-cell activity through two primary mechanisms:
Diagnostic/Research Use: Bind stably to surface CD3ε without activating T-cells, enabling flow cytometry identification of T-cell populations .
Therapeutic Use: Engineered Fc-silent variants (e.g., Teplizumab) or bispecific formats (e.g., Catumaxomab) induce controlled T-cell activation or redirected cytotoxicity .
For example, Teplizumab—a humanized anti-CD3E monoclonal antibody—delays type 1 diabetes progression by resetting autoreactive T-cells . Bispecific antibodies like CD3E-CD20 engage T-cells to lyse B-cell malignancies .
Biotium’s SK7 antibody demonstrates validated performance in identifying T-cells across tissues (peripheral blood, spleen, lymph nodes) with multiple fluorescent conjugates :
Recent advances include:
Immunotoxins: S-CD3e-IT (streptavidin-ZAP conjugate) shows reduced vascular leakage compared to first-gen counterparts .
T-cell Engagers (TCEs): Bispecific antibodies (e.g., hCD3.1-mCD20) achieve >90% B-cell depletion in preclinical models .
Emerging applications focus on: